Myelofibrosis: Emerging JAK2 Inhibitor Combination Treatment Strategies

As data from studies utilizing novel IFN-α therapeutic regimens mature and significant clinical improvements are further elucidated, it is imperative that European-based healthcare professionals involved in the care of patients with PV and ET are provided with expert review and analysis of the most pertinent clinical data pertaining to optimal first- and second-line cytoreductive strategies and guidance for their integration into everyday clinical practice for the enhancement of patient outcomes and quality of life.

To this end, this webcast highlights the clinically significant information presented during the MPN Therapies: Emerging Concepts for Enhanced Outcomes symposium held in Zagreb, Croatia on May 6, 2016.

In this presentation, Dr. Franscisco Cervantes discusses emerging JAK2 inhibitor combination treatment strategies.

Earn accreditation for this activity at the following location:

© 2016 Imedex, LLC.